A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer.

Trial Profile

A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vitespen (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2009 Actual end date (1 Nov 2007) added as reported by ClinicalTrials.gov.
    • 06 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2008 A poster presentation will be made at the Annual Meeting of the American Society of Clinical Oncology in May-June.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top